Hormonal
Beetroot juice supplementation significantly lowers systolic blood pressure in normotensive and hypertensive individuals, primarily through the nitrate-nitrite-nitric oxide pathway, though effects may be attenuated in diabetic patients or by factors that disrupt oral bacterial conversion.
For blood pressure management, beetroot juice (typically 250-500ml) may offer a modest reduction in systolic pressure, especially if you are hypertensive. However, do not rely on it if you have diabetes, as studies show inconsistent results in this group. Crucially, avoid using antibacterial mouthwash around the time of consumption, as the oral bacteria required to activate the nitrate are essential for the effect.
The significant blood pressure lowering effect has been seen among normotensive subjects, which tend to be more considerable among hypertensive individuals... The overall results were ultimately found to be mostly inconsistent... no significant decrease of blood pressure has been admitted in diabetic patients... The reason for this discrepant result is unclear but may reflect... aberrant vascular physiology in diabetic patients
Why this rating
The paper is a review of multiple studies with inconsistent results, noting that while many show benefit, others show no effect, particularly in specific subgroups.
Source
Functional properties of beetroot (Beta vulgaris) in management of cardio-metabolic diseases
Parvin Mirmiran et al. · Nutrition & Metabolism · 2020
DOI 10.1186/s12986-019-0421-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →